5
Elder Project
524788 BSE
Elder Project
Healthcare BSE: 524788 Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has reduced debt.
- Debtor days have improved from 49.6 to 28.0 days.
Weaknesses
5- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.54% over past five years.
- Company has a low return on equity of -11.3% over last 3 years.
- Earnings include an other income of Rs.1.63 Cr.
- Company's cost of borrowing seems high
Growth Rate
Revenue Growth
58% higher than
3Y
Net Income Growth
28% higher than
3Y
Quarterly Results
| Particulars | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.91 | 0.52 | 0.01 | 0.43 | 0.58 | 0.24 | 0.98 | 1.02 | 0.19 |
| Expenses | 0.14 | 1.09 | 0.47 | 0.52 | 0.71 | 0.57 | 0.73 | 0.84 | 0.45 |
| Operating Profit | 0.77 | -0.57 | -0.46 | -0.09 | -0.13 | -0.33 | 0.25 | 0.18 | -0.26 |
| OPM % | 84.62% | -109.62% | -4600% | -20.93% | -22.41% | -137.5% | 25.51% | 17.65% | -136.84% |
| Other Income | -0.41 | 1.32 | 0.28 | 0.28 | 0.27 | 0.64 | 0.35 | 0.32 | 0.32 |
| Interest | 0.86 | 0.79 | 0.96 | 0.98 | 0.95 | 1.4 | 0.74 | 0.74 | 0.72 |
| Depreciation | 0.14 | 0.08 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 |
| PBT | -0.64 | -0.12 | -1.27 | -0.92 | -0.94 | -1.22 | -0.27 | -0.37 | -0.79 |
| Tax % | -23.44% | 50% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.5 | -0.18 | -1.27 | -0.92 | -0.93 | -1.22 | -0.27 | -0.36 | -0.79 |
| EPS in Rs | -1.55 | -0.56 | -3.93 | -2.85 | -2.88 | -3.77 | -0.84 | -1.11 | -2.44 |
Profit & Loss
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 15m | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 11.72 | 3.1 | 4.88 | 5.62 | 6.84 | 8.62 | 9.71 | 6.39 | 2.43 |
| Expenses | 11.58 | 3.39 | 4.66 | 5.04 | 5.53 | 6.37 | 7.52 | 4.92 | 2.59 |
| Operating Profit | 0.14 | -0.29 | 0.22 | 0.58 | 1.31 | 2.25 | 2.19 | 1.47 | -0.16 |
| OPM % | 1.19% | -9.35% | 4.51% | 10.32% | 19.15% | 26.1% | 22.55% | 23% | -6.58% |
| Other Income | 4.06 | 0.82 | 0.99 | 2.21 | 0.54 | 0.63 | 1.51 | 1.53 | 1.63 |
| Interest | 1.48 | 1.7 | 1.6 | 3.67 | 1.96 | 2.26 | 2.8 | 2.68 | 3.6 |
| Depreciation | 0.37 | 0.4 | 0.53 | 0.54 | 0.55 | 0.58 | 0.6 | 0.6 | 0.52 |
| PBT | 2.35 | -1.57 | -0.92 | -1.42 | -0.66 | 0.04 | 0.3 | -0.28 | -2.65 |
| Tax % | 7.66% | -36.94% | -66.3% | 16.9% | -1.52% | 175% | 83.33% | 25% | — |
| Net Profit | 2.17 | -0.99 | -0.31 | -1.66 | -0.65 | -0.03 | 0.06 | -0.34 | -2.64 |
| EPS in Rs | 6.71 | -3.06 | -0.96 | -5.13 | -2.01 | -0.09 | 0.19 | -1.05 | -8.16 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.23 | 3.23 | 3.23 | 3.23 | 3.23 | 3.23 | 3.23 | 3.23 |
| Reserves | 2.32 | 1.33 | 1.02 | -0.64 | -1.29 | -1.32 | -1.27 | -1.61 |
| Borrowings | 15.2 | 21.36 | 35.35 | 28.17 | 15.64 | 18.72 | 20.96 | 20.03 |
| Other Liabilities | 3.02 | 2.99 | 4.47 | 1.95 | 4.26 | 1.43 | 1.8 | 2.91 |
| Total Liabilities | 23.77 | 28.91 | 44.07 | 32.71 | 21.84 | 22.06 | 24.72 | 24.56 |
| Fixed Assets | 5.06 | 6.15 | 6.71 | 6.4 | 6.02 | 6.25 | 6.09 | 4.43 |
| CWIP | 0 | 0.67 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 7.33 | 7.34 | 7.34 | 7.34 | 7.34 | 7.34 | 7.34 | 7.39 |
| Other Assets | 11.38 | 14.75 | 30.02 | 18.97 | 8.48 | 8.47 | 11.29 | 12.74 |
| Total Assets | 23.77 | 28.91 | 44.07 | 32.71 | 21.84 | 22.06 | 24.72 | 24.56 |
Cash Flow
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 |
|---|---|---|---|---|---|---|---|---|
| Operating | -0.27 | -9.14 | -10.81 | 16.24 | 4.52 | 9.24 | 2.95 | 1.51 |
| Investing | 0.67 | -1.99 | -0.03 | -0.06 | 0.36 | -0.58 | -1.08 | 0.95 |
| Financing | -0.33 | 11.18 | 12.99 | -8.79 | -14.49 | -8.69 | -1.75 | -2.68 |
| Net Cash Flow | 0.07 | 0.05 | 2.15 | 7.39 | -9.61 | -0.03 | 0.12 | -0.22 |
| Free Cash Flow | -0.6 | -11.3 | -11.23 | 16.01 | 4.34 | 8.48 | 2.52 | 2.46 |
| CFO/OP | -193 | 3,152 | -4,914 | 2,800 | 348 | 412 | 135 | 103 |
Ratios
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 70.38 | 50.63 | 11.97 | 14.94 | 13.34 | 34.3 | 86.46 | 27.99 |
| Inventory Days | 20.38 | 692 | 190 | 193 | 181 | 150 | 151 | — |
| Days Payable | 129 | 1,460 | 428 | 463 | 413 | 329 | 360 | — |
| Cash Conversion Cycle | -38.7 | -718 | -227 | -256 | -219 | -145 | -122 | 27.99 |
| Working Capital Days | 246 | 1,256 | 1,626 | 383 | 143 | 21.17 | 84.95 | 84.54 |
| ROCE % | — | 0.56% | 2.08% | 6.4% | 5.38% | 12.14% | 13.46% | 9.96% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Elder Project insights
64 extracted metrics + investor summaries across FY06–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Change in Management
7h - Madhu Sundar elevated to Global Head Quality & PV; multiple senior roles revised, effective April 1, 2026. 7h - Madhu Sundar elevated to Global Head Quality & PV; multiple senior roles revised, effective April 1, 2026.
2
Rumour verification - Regulation 30(11)
3h - Delhi HC (09-Mar-2026) upheld manufacturing/export permission for semaglutide; refused interim injunction. 3h - Delhi HC (09-Mar-2026) upheld manufacturing/export permission for semaglutide; refused interim injunction.
3
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
2h - DOJ closed FCPA inquiry on March 5, 2026; no enforcement recommended. 2h - DOJ closed FCPA inquiry on March 5, 2026; no enforcement recommended.
4
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
11h - EIR received March 4, 2026: USFDA classified Srikakulam facility inspection as VAI; inspection closed. 11h - EIR received March 4, 2026: USFDA classified Srikakulam facility inspection as VAI; inspection closed.
5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
27 Feb - Group meetings: 04.03.2026 Ambit Capital (Hyderabad, in-person); 05.03.2026 Goldman Sachs (virtual). 27 Feb - Group meetings: 04.03.2026 Ambit Capital (Hyderabad, in-person); 05.03.2026 Goldman Sachs (virtual).
Frequently Asked Questions about Elder Project
What does Elder Project Ltd do?
Elder Project Limited, incorporated in India, Listed on the Bombay Stock exchange Limited, the company is engaged in Pharmaceutical Manufacturing activities
Where is Elder Project Ltd (524788) listed?
Elder Project Ltd trades under code 524788 on the BSE.
Which sector does Elder Project Ltd belong to?
Elder Project Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Elder Project Limited, incorporated in India, Listed on the Bombay Stock exchange Limited, the company is engaged in Pharmaceutical Manufacturing activities
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524788.md for Elder Project Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.